JPRN-UMIN000052228
Recruiting
未知
Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01) - Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01)
department of respiratory medicine hirosaki university graduate school of medicine0 sites300 target enrollmentSeptember 18, 2023
Conditionsnon small cell carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non small cell carcinoma
- Sponsor
- department of respiratory medicine hirosaki university graduate school of medicine
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 Positive for genetic mutations (EGFR common mutation/ALK), LCNEC 2 The attending physician has deemed the patient ineligible for registration in this study. 3 Has an active concurrent cancer that affects prognosis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study)Type 2 DiabetesTCTR20191213002G Life Sciences433
Completed
Phase 2
Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.Burkitt lymphomahighly aggressive B cell lymphoma10025320NL-OMON36941Vrije Universiteit Medisch Centrum22
Active, not recruiting
Not Applicable
A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease.Burkitt lymphomaMedDRA version: 14.1Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-003141-16-NLVU University Medical Center
Completed
Not Applicable
Assessment of safety and initial therapeutic efficacy of non-damaging patterned scanning laser phototherapy in patients with diffuse diabetic macular edemaDiffuse diabetic macular edemaJPRN-UMIN000012401agoya City University Gradate School of Medical Sciences10
Active, not recruiting
Not Applicable
COMET TrialJPRN-jRCTs031180210Yokote Koutaro60